Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. […]
Novo Nordisk
Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires
Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired. The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on Dec. 24, 2021. […]
Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes
The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms. To accelerate efforts to mine genetic data for insights into mechanisms — and eventually rationally design treatments — the trio of entities launched the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease based […]
Walmart teams up with Novo Nordisk to launch private-brand analog insulin
Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin. Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The […]
Bigfoot Biomedical wins FDA clearance for smart insulin pen cap system
Bigfoot Biomedical announced today that it received FDA 510(k) clearance for its Bigfoot Unity diabetes management system. Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release. Get the full story at our sister site, […]
Once-a-week insulin dosing shows promise in studies
Studies suggest that a new once-per-week injectable insulin therapy is safe and as effective as daily injections for those with type 2 diabetes. Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according […]
The top 5 pharma firms by reputation
Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance. Now ranked eighth overall, the pharma industry came in just ahead of […]
7 medtech advances to improve diabetes treatment
Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]
Insulet wins FDA nod for Omnipod with Novo Nordisk’s Fiasp insulin
Insulet (NSDQ:PODD) said last week that it won FDA clearance for the use of Novo Nordisk‘s (NYSE:NVO) Fiasp insulin with the Omnipod insulin management platform. Acton, Mass.-based Insulet said it completed extensive testing to ensure that Fiasp is safe and usable with the Omnipod and Omnipod Dash systems. It’s the first insulin pump in the U.S. […]
FDA OKs Novo Nordisk’s Fiasp for infusion pumps
Novo Nordisk (NYSE:NVO) said today that it won an expanded label from the FDA for its Fiasp fast-acting insulin aspart injection for use with infusion pumps by adults with Type 1 or Type 2 diabetes. Fiasp won FDA approval in 2017 for use in intravenous infusion under professional supervision or by subcutaneous multiple daily injection in […]
Abbott, Medtronic ink diabetes pacts with Sanofi, Novo Nordisk
Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) today announced separate data-sharing deals for digital diabetes management solutions. Abbott is partnering with Sanofi (NYSE:SNY) to integrate glucose sensing and insulin delivery to help people manage their diabetes. The two companies plan to develop tools to combine Abbott’s FreeStyle Libre technology with insulin dosing information for smart pens, insulin titration apps and cloud software. […]